The past 5–10 years have witnessed remarkable progress in applying genomics, proteomics, and metabolomics to kidney and liver transplant medicine. Genomic tools are uncovering polymorphisms and gene expression signatures that predict rejection or identify tolerance, as well as informing tailored drug dosing. Proteomic studies have yielded noninvasive protein biomarkers (chemokines, injury molecules) for early rejection detection and provided mechanistic insights into how rejection alters graft metabolism and immunity. Metabolomic profiling has revealed distinctive metabolic fingerprints of rejection – such as alterations in amino acid, bile acid, and energy pathways – and even suggested metabolites that correlate with tolerant immune states. These omics advancements are coalescing into a precision immunosuppression paradigm, wherein therapy is customized to the individual patient’s molecular risk profile. Key research initiatives and consortia have driven discovery, and now attention is turning to clinical validation and implementation. In the coming years, we can expect multi-omics biomarker panels and AI-driven models to become part of routine transplant care, enabling clinicians to anticipate rejection, confidently minimize immunosuppression when possible, and intervene early to protect the graft when needed. This omics-enabled approach aims to improve long-term transplant outcomes by achieving the “Goldilocks” balance – just the right level of immunosuppression for each patient – thereby fostering durable graft survival with minimal complications. The state-of-the-art developments reviewed here represent significant strides toward that goal, and ongoing research continues to expand the frontier of transplant precision medicine.